An Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice

Inclusion Criteria: * Men and women aged 18 to 65 years; * BMI 18.5 - 40; * Verified diagnosis: chronic acalculous cholecystitis; * Voluntary desire to provide informed consent to participate in the study Exclusion Criteria: * Presence of stones in the gall bladder and bile ducts; * The presence of jaundice, cholestatic liver diseases, liver cirrhosis with decompensation; * Increased ALT, AST above the 3 upper limits of normal; * Hypersensitivity to the components of the drug Odeston; * Pregnancy and lactation; * Prolonged fasting and total parenteral nutrition; * Patients with symptoms of acute abdomen at the time of inclusion in the study; * Patients with symptoms of acute neurological pathology at the time of inclusion in the study and/or аcute cerebrovascular accident, a history of convulsive syndrome; * Presence of cancer; * Acute infectious diseases at the time of inclusion in the study; * Fever of any origin (above 37.5 C); * Patients with symptoms of heart failure; * Patients with symptoms of pulmonary failure; * Patients with symptoms of acute or chronic renal failure; * A decompensated form of diabetes; * Patients with signs of psychiatric disorders.